Impact of Genetic Mutations on Response and Time to Progression After Radioembolization of Breast Cancer Liver Metastases.

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology Pub Date : 2026-04-21 DOI:10.1016/j.jvir.2026.108819

Bajnauth Daana, Deipolyi Amy, Annie Frank, Bryce Yolanda

{"title":"Impact of Genetic Mutations on Response and Time to Progression After Radioembolization of Breast Cancer Liver Metastases.","authors":"Bajnauth Daana, Deipolyi Amy, Annie Frank, Bryce Yolanda","doi":"10.1016/j.jvir.2026.108819","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the association between genetic mutations and clinical outcomes, including response and time to progression, in patients with breast cancer liver metastasis treated with Y-90 radioembolization.Materials and methods: This is a retrospective, single-institution study. 110 female patients with breast cancer liver metastasis who underwent Y-90 radioembolization were included. Genomic profiling was conducted using MSK-IMPACT. Patient demographics and treatment response were collected from electronic medical records and Picture Archiving and Communication System (PACS). Y-90 response was categorized as complete, partial, none, or progression. Time to progression was analyzed in patients with an initial response. Median survival using Kaplan Meier estimation was correlated to genetic mutations. 17 patients died before progression was assessed, and 6 patients were not yet evaluated post-procedure.Results: Overall median survival was 32.8 months (1.3 - 173.0). Patients with the ERBB2 mutation showed the longest median survival (70.2 months [12.5 - 173.0]), while the RAD21 mutation had the shortest median survival (25.5 months [2.4 - 173.0]). KDM5C and CBFB mutations were associated with the highest response rates (100%, p=0.003 and p=0.014, respectively), while the H3C13 mutation was associated with the lowest response rate (0%, p=0.002). Median time to progression was 32.8 months (1.4 - 173.0) in patients with an initial treatment response. The H3F3B mutation was associated with the longest time to progression (105 months [50.2 - 105.0]), while the RUNX1 mutation was associated with the shortest time to progression (1.4 months [1.4 - 36.5]).Conclusion: Specific genetic mutations are associated with survival, response rate, and time to progression after Y-90 radioembolization. This study underscores the potential use of genetic profiling to individualize treatment plans.","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"108819"},"PeriodicalIF":2.6000,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular and Interventional Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jvir.2026.108819","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the association between genetic mutations and clinical outcomes, including response and time to progression, in patients with breast cancer liver metastasis treated with Y-90 radioembolization.

Materials and methods: This is a retrospective, single-institution study. 110 female patients with breast cancer liver metastasis who underwent Y-90 radioembolization were included. Genomic profiling was conducted using MSK-IMPACT. Patient demographics and treatment response were collected from electronic medical records and Picture Archiving and Communication System (PACS). Y-90 response was categorized as complete, partial, none, or progression. Time to progression was analyzed in patients with an initial response. Median survival using Kaplan Meier estimation was correlated to genetic mutations. 17 patients died before progression was assessed, and 6 patients were not yet evaluated post-procedure.

Results: Overall median survival was 32.8 months (1.3 - 173.0). Patients with the ERBB2 mutation showed the longest median survival (70.2 months [12.5 - 173.0]), while the RAD21 mutation had the shortest median survival (25.5 months [2.4 - 173.0]). KDM5C and CBFB mutations were associated with the highest response rates (100%, p=0.003 and p=0.014, respectively), while the H3C13 mutation was associated with the lowest response rate (0%, p=0.002). Median time to progression was 32.8 months (1.4 - 173.0) in patients with an initial treatment response. The H3F3B mutation was associated with the longest time to progression (105 months [50.2 - 105.0]), while the RUNX1 mutation was associated with the shortest time to progression (1.4 months [1.4 - 36.5]).

Conclusion: Specific genetic mutations are associated with survival, response rate, and time to progression after Y-90 radioembolization. This study underscores the potential use of genetic profiling to individualize treatment plans.

查看原文本刊更多论文

基因突变对乳腺癌肝转移放射栓塞后反应和进展时间的影响。

目的：评估Y-90放射栓塞治疗乳腺癌肝转移患者的基因突变与临床结果（包括反应和进展时间）之间的关系。材料和方法：这是一项回顾性、单机构研究。110例女性乳腺癌肝转移患者行Y-90放射栓塞治疗。使用MSK-IMPACT进行基因组分析。通过电子病历和图片存档和通信系统（PACS）收集患者人口统计数据和治疗反应。Y-90反应分为完全、部分、无或进展。对有初始反应的患者进行进展时间分析。Kaplan Meier估计的中位生存期与基因突变相关。17例患者在评估进展前死亡，6例患者术后尚未评估。结果：总中位生存期为32.8个月（1.3 - 173.0个月）。ERBB2突变患者的中位生存期最长（70.2个月[12.5 - 173.0]），RAD21突变患者的中位生存期最短（25.5个月[2.4 - 173.0]）。KDM5C和CBFB突变与最高应答率相关（100%,p=0.003和p=0.014），而H3C13突变与最低应答率相关（0%,p=0.002）。初始治疗反应的患者中位进展时间为32.8个月（1.4 - 173.0）。H3F3B突变与最长进展时间相关（105个月[50.2 - 105.0]），而RUNX1突变与最短进展时间相关（1.4个月[1.4 - 36.5]）。结论：特定的基因突变与Y-90放射栓塞后的生存率、反应率和进展时间有关。这项研究强调了基因图谱在个性化治疗计划中的潜在应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Vascular and Interventional Radiology 医学-核医学

CiteScore

4.30

自引率

10.30%

发文量

942

审稿时长

90 days

期刊介绍： JVIR, published continuously since 1990, is an international, monthly peer-reviewed interventional radiology journal. As the official journal of the Society of Interventional Radiology, JVIR is the peer-reviewed journal of choice for interventional radiologists, radiologists, cardiologists, vascular surgeons, neurosurgeons, and other clinicians who seek current and reliable information on every aspect of vascular and interventional radiology. Each issue of JVIR covers critical and cutting-edge medical minimally invasive, clinical, basic research, radiological, pathological, and socioeconomic issues of importance to the field.